Bevacizumab-based triplet versus doublet chemotherapy as first-line treatment for metastatic right-sided colon cancer: Results of the KCSG CO19-18 phase II trial
Abstract
e15562
Background:
The prognostic significance of primary tumor location in colorectal cancer has recently gained attention. Previous studies have demonstrated poorer outcomes of cetuximab-based therapy in right-sided colon cancer. Therefore, we conducted a multicenter, prospective, open-label, randomized phase II trial to evaluate the efficacy of bevacizumab plus FOLFOXIRI (A-FOLFOXIRI) versus bevacizumab plus FOLFOX/FOLFIRI (A-FOLFOX/FOLFIRI) in patients with unresectable right-sided colorectal cancer with poor prognosis (KCSG CO19-18; NCT03641976).
Methods:
Previously untreated patients with metastatic right-sided colon cancer (cecum to splenic flexure) were enrolled. Patients were stratified by ECOG performance status (0 vs 1–2), prior adjuvant chemotherapy (yes vs no), and participating center, and randomly assigned (1:1) to receive A-FOLFOXIRI (experimental arm) or A-FOLFOX/FOLFIRI (control arm). Treatment was administered every 2 weeks for up to 12 cycles, followed by investigator-determined continuation until disease progression, withdrawal of consent, or unacceptable toxicity. Maintenance therapy with bevacizumab, fluorouracil, and leucovorin was permitted in cases of intolerance to oxaliplatin or irinotecan. The primary endpoint was the 6-month progression-free survival (PFS) rate. Secondary endpoints included median overall survival, median PFS, objective response rate (ORR), and safety.
Results:
From December 2018 to February 2024, 61 patients were enrolled…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Antioxidant efficacy and the upregulation of Nrf2-mediated HO-1 expression by (+)-lariciresinol, a lignan isolated from Rubia philippinensis, through the activation of p38
- Anti-influenza virus activity of green tea by-products in vitro and efficacy against influenza virus infection in chickens
- Therapeutic Potential of Mesenchymal Stem Cells (MSCs) and MSC-Derived Extracellular Vesicles for the Treatment of Spinal Cord Injury
- The intratumoral administration of ferucarbotran conjugated with doxorubicin improved therapeutic effect by magnetic hyperthermia combined with pharmacotherapy in a hepatocellular carcinoma model
- Enhanced anticancer efficacy of TRAIL-conjugated and odanacatib-loaded PLGA nanoparticles in TRAIL resistant cancer
- In vivo tracking of bioorthogonally labeled T-cells for predicting therapeutic efficacy of adoptive T-cell therapy
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.